SRx Health Solutions and EMJX Invest in Recent IPO and Commercial-Stage Pharmaceutical Company of Psychedelics, Optimi Health Corp. (OPTH)

SRx Health Solutions (NYSE American: SRXH) and merger partner EMJX have invested in Optimi Health (NASDAQ: OPTH), a commercial-stage pharmaceutical company producing GMP-grade psychedelic drug products such as psilocybin for mental health therapies.

Rhea-AI Summary

SRx Health Solutions (NYSE American: SRXH) and merger partner EMJX have invested in Optimi Health (NASDAQ: OPTH), a commercial-stage pharmaceutical company producing GMP-grade psychedelic drug products such as psilocybin for mental health therapies.

The investment was identified by EMJX’s AI-driven platform, citing about 30% insider ownership, institutional participation, strong management insider IPO participation, and governance led by chairman John James (JJ) Wilson. Tailwinds include an April 2026 U.S. executive order to accelerate psychedelic drug development. SRx has filed a Form S-4 related to its proposed merger with EMJX.

Positive

• EMJX AI platform selects Optimi Health as an investment opportunity
• Optimi Health insider ownership of approximately 30%
• Optimi Health has about 5.6 million shares outstanding
• Institutional and management insider participation in Optimi Health IPO
• Industry support from April 2026 U.S. executive order on psychedelics
• SRx files Form S-4 for proposed merger with EMJX

Negative

• None.

Argus May 21 session

+9.79% close to close Open Argus

Details

News Market Reaction – SRXH

On May 21, the day this news came out, SRXH closed 9.79% above the previous close.

Data tracked by StockTitan Argus for the May 21 session.

Market Context

On May 21, the day this news came out, the stock closed 9.8% above the previous close. A strong posi...

Analysis

On May 21, the day this news came out, the stock closed 9.8% above the previous close. A strong positive reaction aligns with SRx Health’s pattern of using strategic investments and mergers to reposition the business. This IPO investment in Optimi Health, a commercial-stage psychedelics company, would fit alongside prior AI and space‑theme allocations. Investors could weigh how incremental exposure to new themes interacts with historical dilution from equity lines and preferred stock, and whether past post‑news moves, including swings of 25.75%, suggest volatility risk after initial enthusiasm.

Historical Context

5 past events · Latest: May 15

5 events

1. May 15

   Profit dividend plan

   24h Move

   -9.4%

   Plan to dividend 75% of profits from Astro Investment XVII to shareholders.

2. May 14

   Earnings update

   24h Move

   -9.4%

   Q2 2026 results with higher revenue, better margins, and improved losses.

3. May 13

   AI/space investment

   24h Move

   +25.8%

   Investment of over 10% of investable capital into Astro Investment XVII SPV.

4. Apr 22

   Astro capital stake

   24h Move

   +1.7%

   Investment exceeding 10% of investable capital into AI and space‑focused SPV.

5. Apr 17

   Merger update

   24h Move

   -0.6%

   Shareholder letter on EMJX merger progress and strong digital‑asset returns.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

gmp-grade, psychedelic, psilocybin, executive order, +2 more

6 terms

gmp-grade medical

"focused on manufacturing and distribution of GMP-grade psychedelic drug products"

GMP-grade means a drug substance, ingredient or product was manufactured under Good Manufacturing Practice standards — a set of rules and documented controls that ensure consistent cleanliness, quality and traceability. For investors, GMP-grade items matter because they lower regulatory and safety risk, make products eligible for approval and sale in regulated markets, and reduce the chance of costly recalls or supply disruptions; think of it like food prepared in a certified commercial kitchen rather than a home stove.

psychedelic medical

"GMP-grade psychedelic drug products for mental health therapies including Psilocybin."

Psychedelic describes a class of drugs or compounds that temporarily change a person’s perception, mood and thinking—often causing vivid sensory experiences or altered awareness. For investors, psychedelics matter because they are the focus of medical research and potential treatments, so regulatory approvals, clinical trial results, patent protection and public acceptance can suddenly change a company’s value, similar to how a new technology or medicine can create a whole new market.

psilocybin medical

"GMP-grade psychedelic drug products for mental health therapies including Psilocybin."

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

executive order regulatory

"after U.S. President Trump signed an executive order in April 2026 to accelerate"

An executive order is a formal directive issued by a country’s chief executive (for example, a president or prime minister) that tells government agencies how to apply or enforce laws and policies without waiting for new legislation. It matters to investors because these orders can quickly change rules, permits, taxes, trade or regulatory enforcement—like a manager changing company policy overnight—creating risks or opportunities that can affect company costs, revenues and share prices.

registration statement on form s-4 regulatory

"filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement")"

A registration statement on Form S-4 is a formal filing with the U.S. Securities and Exchange Commission used when a company issues shares or other securities as part of a merger, acquisition, exchange offer or similar corporate deal. It bundles the transaction terms, financial statements, risk factors and shareholder vote materials so investors can assess the deal; think of it as a detailed prospectus or buyer’s packet that explains what you would own and how the deal could change your stake.

information statement/prospectus regulatory

"The Registration Statement includes an information statement of the Company and a prospectus"

A prospectus or information statement is a formal document that lays out key facts about a company, an offer of securities, or a proposed corporate action so investors can make informed choices. Think of it as a product label that explains what is being sold, the risks, the company’s finances and how proceeds will be used; investors rely on it to compare options and judge whether the potential reward justifies the risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NORTH PALM BEACH, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") and EMJ Crypto Technologies ("EMJX"), a digital-asset treasury operating platform with which the Company has entered into a definitive merger agreement, today announced investing in Optimi Health Corp. (NASDAQ: OPTH), a commercial-stage pharmaceutical company focused on manufacturing and distribution of GMP-grade psychedelic drug products for mental health therapies including Psilocybin.

The EMJX proprietary operating system applying quantitative models, artificial intelligence and systematic risk controls has identified Optimi Health Corp. as an investment opportunity for several reasons including high insider ownership of approximately 30% and strong corporate governance led by Chairman of the Board whose family founded Lululemon, John James (JJ) Wilson.

Additionally, the psychedelic industry is experiencing tailwinds after U.S. President Trump signed an executive order in April 2026 to accelerate psychedelic drug development and improve timelines and coordination with the FDA and DEA.

“Our proprietary AI technology investment platform can guide and identify investment themes,” said Michael Young, SRx Board Member. “This gives us a unique opportunity to invest in companies with positive macro and industry trends. Optimi has approximately 5.6 million shares outstanding, institutional ownership, as well as strong participation by management insiders on the IPO.”

Additional Information and Where to Find It
In connection with the proposed transaction between the Company has filed with the SEC a Registration Statement on Form S-4 (the "Registration Statement") to register the common stock to be issued in connection with the proposed transaction. The Registration Statement includes an information statement of the Company and a prospectus of the Company (the "Information Statement/Prospectus"), and each of EMJX and the Company may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Information Statement/Prospectus will be sent to the stockholders This is not a substitute for the Registration Statement, the Information Statement/Prospectus or any other relevant documents that EMJX or the Company has filed or will file with the SEC. BEFORE MAKING ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND INFORMATION STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT EMJX, THE COMPANY, THE PROPOSED TRANSACTION, AND RELATED MATTERS. A copy of the Registration Statement, Information Statement/Prospectus, as well as other relevant documents filed by EMJX and the Company with the SEC, may be obtained free of charge, when they become available, at the SEC's website at www.sec.gov. The information on EMJX's or the Company's respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.

No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "intend," "aim," "plan," "may," "could," "target," and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.

Company Contact
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer

Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
valter@kcsa.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SRx Health Solutions (SRXH) announce about its investment in Optimi Health (OPTH)?

SRx Health Solutions and EMJX announced an investment in Optimi Health, a commercial-stage psychedelic pharmaceutical company. According to SRx, Optimi manufactures and distributes GMP-grade psychedelic drug products, including psilocybin, for mental health therapies and was selected by EMJX’s AI-driven investment platform.

Why did EMJX’s AI platform select Optimi Health (OPTH) for investment by SRx Health (SRXH)?

EMJX’s AI platform identified Optimi Health due to factors like around 30% insider ownership and strong corporate governance. According to the companies, institutional ownership and significant management insider participation in Optimi’s IPO also supported the decision to invest.

How does the April 2026 U.S. executive order affect SRx Health’s investment in Optimi Health?

The April 2026 U.S. executive order aims to accelerate psychedelic drug development and coordination with the FDA and DEA. According to SRx, this creates industry tailwinds that support Optimi Health’s focus on GMP-grade psychedelic therapies and underpins the strategic rationale for the investment.

What are the key ownership details of Optimi Health (OPTH) cited by SRx Health (SRXH)?

SRx highlights Optimi Health’s approximately 30% insider ownership and about 5.6 million shares outstanding. According to the company, Optimi also has institutional ownership and strong participation by management insiders in its IPO, factors seen as supportive of governance and alignment.

What is the relationship between SRx Health Solutions (SRXH) and EMJX in this Optimi Health investment?

SRx Health and EMJX jointly invested in Optimi Health and are parties to a definitive merger agreement. According to SRx, a Form S-4 registration statement has been filed with the SEC in connection with the proposed transaction between SRx and EMJX.

Who leads corporate governance at Optimi Health (OPTH) mentioned by SRx Health (SRXH)?

Corporate governance at Optimi Health is led by chairman John James (JJ) Wilson. According to SRx, Wilson’s family founded Lululemon, and his role is one of several governance factors considered in EMJX’s AI-driven assessment of the investment.

What SEC filing did SRx Health (SRXH) make related to its merger with EMJX?

SRx Health filed a Registration Statement on Form S-4 with the SEC for the proposed merger with EMJX. According to the company, this filing includes an information statement and prospectus that will be sent to stockholders once the registration becomes effective.